<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505010</url>
  </required_header>
  <id_info>
    <org_study_id>INSPiRED, version 4.0</org_study_id>
    <nct_id>NCT01505010</nct_id>
  </id_info>
  <brief_title>Renal Denervation for Management of Drug-Resistant Hypertension</brief_title>
  <acronym>INSPiRED</acronym>
  <official_title>Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INSPiRED is a multicenter parallel-group trial comparing usual medical treatment (control
      group) or usual medical treatment plus renal denervation (intervention). In both groups
      adherence will be monitored both before randomization and during 36 months of follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      To compare the blood pressure lowering efficacy and safety of renal denervation vs. usual
      medical therapy. The primary endpoints for efficacy and safety are the baseline-adjusted
      between-group differences in 24-h systolic blood pressure and in glomerular filtration rate
      as estimated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
      Secondary endpoints for efficacy and safety include other indexes of blood pressure control
      and renal function, metabolic variables and morbidity and mortality. These endpoints will be
      assessed 6 months after randomization.

      Trial design:

      Randomized controlled trial with blinded assessment of the primary and secondary endpoints.
      The study consists of 6 stages. Supervised and nonsupervised follow-up refer to assessment of
      outcome at or outside the participating center, respectively.

        -  Screening involves checking eligibility and ruling out secondary hypertension.

        -  Run-in period of 3 months to optimize medical treatment and to assess adherence to
           treatment.

        -  Stratification and randomization Eligible patients will be stratified by center and age
           group (adults vs. elderly, 20-49 vs. 50-69 years) and randomized centrally in a
           one-to-one proportion to control or intervention.

        -  Renal sympathetic denervation in the intervention group, patients of the control group
           will be offered renal denervation after 6 months.

        -  Supervised follow-up at 1, 3 and 6 months after randomization.

        -  Long-term supervised or non-supervised follow-up of morbidity and mortality beyond 6
           months and up to 3 years.

      Sample size:

      To detect a 10-mm Hg difference (SD 20 mm Hg) in systolic blood pressure between the
      randomized groups with a 2-sided P-value of 0.01 and 90% power in total 240 patients need to
      be randomized. Allowing 50% screening failures, 480 patients would have to be screened.

      Assessment of adherence:

      Adherence to treatment will be assessed by measurement of drugs or drug metabolites in
      biological fluids. Jung and coworkers developed a liquid chromatography-mass spectrometric
      method that allows detecting all antihypertensive drugs or their metabolites in a single
      urine sample. This obligatory approach will be implemented.

      Assessment of quality of life Assessment of quality of life is compulsory at baseline and at
      each visit during the supervised follow-up, using the EuroQol 5D.

      Assessment of sympathetic modulation:

      heart rate variability (HRV) will be assessed at baseline and at the 6-month follow-up visit,
      based on 15 minutes ECG recordings. A software program, developed in LabVIEW by the group of
      Aubert et al. will be used.

      Relevance:

      INSPiRED differs from previous and ongoing studies in several aspects: (1) a stringent
      selection of patients; (2) drug optimization with assessment of adherence throughout the
      study; (3) out-of-the-office blood pressure for patient selection and follow-up; (4)
      state-of-the-art renal artery imaging by computerized tomographic angiography; (5) validation
      of urinary proteomic biomarkers to predict blood pressure responses and changes in renal
      function; (6) follow-up will be beyond 6 months up to 3 years; (7) use of heart rate
      variability and renal nerve stimulation to assess the completeness of renal denervation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel group trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement)</measure>
    <time_frame>The primary endpoint has been assessed 6 months after randomization.</time_frame>
    <description>The primary endpoint deals with efficacy of renal denervation with regard to controlling blood pressure on ambulatory measurement. It consists of the baseline-adjusted between-group difference in the changes in 24-h systolic blood pressure. Because automated blood pressure monitors will be used, the assessment of the primary endpoint is blind.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Glomerular Filtration Rate</measure>
    <time_frame>This endpoint has been assessed 6 months after randomization.</time_frame>
    <description>The primary endpoint for safety of renal denervation is the baseline-adjusted between group difference in the change of glomerular filtration rate estimated by using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Intensity of Medical Treatment</measure>
    <time_frame>This endpoint will be assessed 6 months after randomization.</time_frame>
    <description>The number and doses of blood-pressure lowering drugs in the 2 arms of the trial.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard antihypertensive drug treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation plus standard antihypertensive drug treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal denervation</intervention_name>
    <description>Renal denervation in the intervention group</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Renal denervation, using an intravascular catheter system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Women and men are eligible. Women of reproductive age should apply effective
             contraception.

          -  Age ranges from 20 years (inclusive) to less than 70 years.

          -  Patients should have essential hypertension.

          -  Treatment-resistant hypertension in patients taking a stable drug regimen for at least
             4 weeks consisting of 3 or more antihypertensive medications from different classes,
             including a diuretic.

          -  Under maximal therapy, office blood pressure should be ≥140/90 mmHg and the 24-h
             ambulatory blood pressure should be 130 mm Hg systolic or 80 mm Hg diastolic or
             higher.

          -  eGFR must be ≥ 60 mL/min/1.73 m2.

          -  The patients should accept to have adherence checked before randomisation and during
             supervised follow-up, but both patients and doctors will remain blinded to the
             results;

          -  Informed written consent.

        Exclusion criteria:

          -  Suboptimal clinical context, because of recent history or concurrent disease.

          -  Isolated systolic and diastolic hypertension.

          -  Body-mass index ≥ 40kg/m2.

          -  The anatomy of the renal arteries is suboptimal for renal denervation.

          -  Pregnancy.

          -  Alcohol or substance abuse or psychiatric illnesses.

          -  Participation in other study.

          -  The clinical context is suboptimal for renal denervation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan A. Staessen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>BE-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>BE-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://www.tandfonline.com/doi/full/10.1080/08037051.2017.1320939</url>
    <description>Article reporting main trial results</description>
  </link>
  <results_reference>
    <citation>Jacobs L, Persu A, Huang QF, Lengelé JP, Thijs L, Hammer F, Yang WY, Zhang ZY, Renkin J, Sinnaeve P, Wei FF, Pasquet A, Fadl Elmula FEM, Carlier M, Elvan A, Wunder C, Kjeldsen SE, Toennes SW, Janssens S, Verhamme P, Staessen JA; European Network Coordinating Research on Renal Denervation. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press. 2017 Dec;26(6):321-331. doi: 10.1080/08037051.2017.1320939. Epub 2017 May 10.</citation>
    <PMID>28489464</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 3, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <results_first_submitted>May 10, 2017</results_first_submitted>
  <results_first_submitted_qc>March 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2020</results_first_posted>
  <last_update_submitted>March 15, 2020</last_update_submitted>
  <last_update_submitted_qc>March 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Jan A. Staessen</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Treatment-resistant hypertension</keyword>
  <keyword>Renal denervation</keyword>
  <keyword>Sympathetic nervous system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized data can be made available via a motivated data transfer request (for scientific purposes only) via the PI (Prof Jan A. Staessen) and pending ethics approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Currently available until 2025</ipd_time_frame>
    <ipd_access_criteria>Ethics approval</ipd_access_criteria>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From 28 March 2014 until 11 May 2016, 3 Belgian centers screened 29 patients, of whom 4 did not meet the criteria to enter the run-in period. Of 25 remaining patients, 8 were not eligible for randomization. Of 17 eligible patients, 9 were randomized to control and 8 to RDN. Of the 8 patients randomized to intervention, two did not undergo RDN.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Standard antihypertensive drug treatment</description>
        </group>
        <group group_id="P2">
          <title>Intervention Group</title>
          <description>Renal denervation plus standard antihypertensive drug treatment
Renal denervation: Renal denervation in the intervention group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treatment resistant hypertensive patients</population>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Standard antihypertensive drug treatment
Renal denervation: Renal denervation in the intervention group</description>
        </group>
        <group group_id="B2">
          <title>Intervention Group</title>
          <description>Renal denervation plus standard antihypertensive drug treatment
Renal denervation: Renal denervation in the intervention group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="8.8"/>
                    <measurement group_id="B2" value="48.4" spread="10.8"/>
                    <measurement group_id="B3" value="48.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement)</title>
        <description>The primary endpoint deals with efficacy of renal denervation with regard to controlling blood pressure on ambulatory measurement. It consists of the baseline-adjusted between-group difference in the changes in 24-h systolic blood pressure. Because automated blood pressure monitors will be used, the assessment of the primary endpoint is blind.</description>
        <time_frame>The primary endpoint has been assessed 6 months after randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Standard antihypertensive drug treatment</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Renal denervation plus standard antihypertensive drug treatment
Renal denervation: Renal denervation in the intervention group</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline to 6 Months on 24-h Ambulatory Measurement (Follow-up Minus Baseline Measurement)</title>
          <description>The primary endpoint deals with efficacy of renal denervation with regard to controlling blood pressure on ambulatory measurement. It consists of the baseline-adjusted between-group difference in the changes in 24-h systolic blood pressure. Because automated blood pressure monitors will be used, the assessment of the primary endpoint is blind.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="-12.0" upper_limit="13.4"/>
                    <measurement group_id="O2" value="-21.7" lower_limit="-33.4" upper_limit="-9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We used mixed models to compare blood pressure changes between randomized groups at 6 months, while adjusting for the baseline blood pressure; statistical significance was a P-value less than 0.05 on two-sided tests.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for the baseline 24-h systolic blood pressure</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.5</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Difference at 6 months in 24-h systolic blood pressure (control minus intervention)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Glomerular Filtration Rate</title>
        <description>The primary endpoint for safety of renal denervation is the baseline-adjusted between group difference in the change of glomerular filtration rate estimated by using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.</description>
        <time_frame>This endpoint has been assessed 6 months after randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Standard antihypertensive drug treatment</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Renal denervation plus standard antihypertensive drug treatment
Renal denervation: Renal denervation in the intervention group</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glomerular Filtration Rate</title>
          <description>The primary endpoint for safety of renal denervation is the baseline-adjusted between group difference in the change of glomerular filtration rate estimated by using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.</description>
          <units>ml/min/1.73 m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" spread="24.1"/>
                    <measurement group_id="O2" value="92.4" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference between control and intervention group at 6 months</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.87</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Intensity of Medical Treatment</title>
        <description>The number and doses of blood-pressure lowering drugs in the 2 arms of the trial.</description>
        <time_frame>This endpoint will be assessed 6 months after randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Standard antihypertensive drug treatment</description>
          </group>
          <group group_id="O2">
            <title>Intervention Group</title>
            <description>Renal denervation plus standard antihypertensive drug treatment
Renal denervation: Renal denervation in the intervention group</description>
          </group>
        </group_list>
        <measure>
          <title>The Intensity of Medical Treatment</title>
          <description>The number and doses of blood-pressure lowering drugs in the 2 arms of the trial.</description>
          <units>number of drugs taken per day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Wilcocon rank sum test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Follow-up at participating clinical centers.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Standard antihypertensive drug treatment</description>
        </group>
        <group group_id="E2">
          <title>Intervention Group</title>
          <description>Renal denervation plus standard antihypertensive drug treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Ethical approval was obtained to randomise 18 patients in a pilot trial, published recently (http://dx.doi.org/10.1080/08037051.2017.1320939)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jan A. Staessen</name_or_title>
      <organization>University of Leuven</organization>
      <phone>+32 16 34 7104</phone>
      <email>jan.staessen@med.kuleuven.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

